Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG4101 in Refractory or Relapsed AML
NCT03349502Phase 2Completed
- Sponsor
- Seoul National University Hospital
- Start
- Nov 2017
- Primary completion
- Mar 2020
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of MG4101 in acute myeloid leukemia (AML), sponsored by Seoul National University Hospital. Started Nov 2017; status: completed.
02
Drugs
MG4101
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03349502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03349502.